Literature DB >> 32038947

Left ventricular fibrosis by extracellular volume fraction and the risk of atrial fibrillation recurrence after catheter ablation.

Songnan Li1, Lei Zhao2, Xiaohai Ma3, Rong Bai1, Jie Tian2, Joseph B Selvanayagam4.   

Abstract

BACKGROUND: Left ventricular (LV) extracellular volume fraction (ECV) provides prognostic information in patients with variety of cardiomyopathies. However, data on the clinical significance of LV ECV in patients with atrial fibrillation (AF), especially in patients without replacement fibrosis are sparse. This study sought to investigate whether the presence of LV fibrosis identified by cardiac magnetic resonance (CMR) ECV quantification would independently predict the recurrence of AF after first catheter ablation (CA) in patients with AF.
METHODS: A total of 130 consecutive patients who were referred for CA of AF underwent CMR examination prior to ablation. LV function, T1 mapping derived LV ECV, LV late gadolinium enhancement (LGE) were assessed. Patients were followed for arrhythmia recurrence after the CA procedure.
RESULTS: Of 130 AF patients, 65 patients had paroxysmal AF, and 65 patients had persistent AF. There were 50 AF recurrences over a median follow-up period of 13 months. LV ECV were significantly higher in patients with recurrent AF compared to those with no recurrence (30.4%±3.3% vs. 27.4%±2.9%, P<0.001). In multivariable model, gender (HR: 0.348, 95% CI: 0.174-0.697, P=0.003), body mass index (BMI) (HR: 1.159, 95% CI: 1.050-1.279, P=0.003), AF duration (HR: 1.006, 95% CI: 1.001-1.011, P=0.017), and LV ECV (HR: 1.158, 95% CI: 1.071-1.251, P=0.000) were significantly associated with AF recurrence. In subgroup of patients without LGE, gender, BMI, AF duration and LV ECV were still the independent predictors of AF recurrence.
CONCLUSIONS: LV ECV expansion is associated with AF recurrence after CA and is a strong independent predictor of AF recurrence. 2019 Cardiovascular Diagnosis and Therapy. All rights reserved.

Entities:  

Keywords:  Atrial fibrillation (AF); extracellular volume fraction (ECV); left ventricular fibrosis (LV fibrosis); recurrence

Year:  2019        PMID: 32038947      PMCID: PMC6987514          DOI: 10.21037/cdt.2019.12.03

Source DB:  PubMed          Journal:  Cardiovasc Diagn Ther        ISSN: 2223-3652


  21 in total

1.  Impact of Female Sex on Clinical Outcomes in the FIRE AND ICE Trial of Catheter Ablation for Atrial Fibrillation.

Authors:  Karl-Heinz Kuck; Josep Brugada; Alexander Fürnkranz; K R Julian Chun; Andreas Metzner; Feifan Ouyang; Michael Schlüter; Arif Elvan; Kendra M Braegelmann; Fred J Kueffer; Thomas Arentz; Jean-Paul Albenque; Michael Kühne; Christian Sticherling; Claudio Tondo
Journal:  Circ Arrhythm Electrophysiol       Date:  2018-05

2.  Risk of death and cardiovascular events in initially healthy women with new-onset atrial fibrillation.

Authors:  David Conen; Claudia U Chae; Robert J Glynn; Usha B Tedrow; Brendan M Everett; Julie E Buring; Christine M Albert
Journal:  JAMA       Date:  2011-05-25       Impact factor: 56.272

3.  Histological evidence of inflammatory reaction associated with fibrosis in the atrial and ventricular walls in a case-control study of patients with history of atrial fibrillation.

Authors:  Lubov B Mitrofanova; Victoria Orshanskaya; Siew Yen Ho; Pyotr G Platonov
Journal:  Europace       Date:  2016-12       Impact factor: 5.214

4.  Prediction of atrial fibrillation recurrence after cardioversion in patients with left-atrial dilation.

Authors:  Cristina Fornengo; Marina Antolini; Simone Frea; Cristina Gallo; Walter Grosso Marra; Mara Morello; Fiorenzo Gaita
Journal:  Eur Heart J Cardiovasc Imaging       Date:  2014-10-01       Impact factor: 6.875

5.  Impact of CARDIOrespiratory FITness on Arrhythmia Recurrence in Obese Individuals With Atrial Fibrillation: The CARDIO-FIT Study.

Authors:  Rajeev K Pathak; Adrian Elliott; Melissa E Middeldorp; Megan Meredith; Abhinav B Mehta; Rajiv Mahajan; Jeroen M L Hendriks; Darragh Twomey; Jonathan M Kalman; Walter P Abhayaratna; Dennis H Lau; Prashanthan Sanders
Journal:  J Am Coll Cardiol       Date:  2015-06-22       Impact factor: 24.094

6.  Incidental LV LGE on CMR Imaging in Atrial Fibrillation Predicts Recurrence After Ablation Therapy.

Authors:  Promporn Suksaranjit; Nazem Akoum; Eugene G Kholmovski; Gregory J Stoddard; Lowell Chang; Kavitha Damal; Krishna Velagapudi; Allen Rassa; Erik Bieging; Shridhar Challa; Imran Haider; Nassir F Marrouche; Christopher J McGann; Brent D Wilson
Journal:  JACC Cardiovasc Imaging       Date:  2015-06-17

7.  Worldwide epidemiology of atrial fibrillation: a Global Burden of Disease 2010 Study.

Authors:  Sumeet S Chugh; Rasmus Havmoeller; Kumar Narayanan; David Singh; Michiel Rienstra; Emelia J Benjamin; Richard F Gillum; Young-Hoon Kim; John H McAnulty; Zhi-Jie Zheng; Mohammad H Forouzanfar; Mohsen Naghavi; George A Mensah; Majid Ezzati; Christopher J L Murray
Journal:  Circulation       Date:  2013-12-17       Impact factor: 29.690

Review 8.  State of the Art: Clinical Applications of Cardiac T1 Mapping.

Authors:  Erik B Schelbert; Daniel R Messroghli
Journal:  Radiology       Date:  2016-03       Impact factor: 11.105

9.  Prospective randomized comparison between a fixed '2C3L' approach vs. stepwise approach for catheter ablation of persistent atrial fibrillation.

Authors:  Jian-Zeng Dong; Cai-Hua Sang; Rong-Hui Yu; De-Yong Long; Ri-Bo Tang; Chen-Xi Jiang; Man Ning; Nian Liu; Xing-Peng Liu; Xin Du; Hung-Fat Tse; Chang-Sheng Ma
Journal:  Europace       Date:  2015-05-08       Impact factor: 5.214

10.  Systolic MOLLI T1 mapping with heart-rate-dependent pulse sequence sampling scheme is feasible in patients with atrial fibrillation.

Authors:  Lei Zhao; Songnan Li; Xiaohai Ma; Andreas Greiser; Tianjing Zhang; Jing An; Rong Bai; Jianzeng Dong; Zhanming Fan
Journal:  J Cardiovasc Magn Reson       Date:  2016-03-15       Impact factor: 5.364

View more
  1 in total

1.  Development and Validation of a Novel Prognostic Model Predicting the Atrial Fibrillation Recurrence Risk for Persistent Atrial Fibrillation Patients Treated with Nifekalant During the First Radiofrequency Catheter Ablation.

Authors:  Youzheng Dong; Zhenyu Zhai; Bo Zhu; Shucai Xiao; Yang Chen; Anxue Hou; Pengtao Zou; Zirong Xia; Jianhua Yu; Juxiang Li
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-22       Impact factor: 3.727

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.